Support For Men With Advanced Prostate Cancer

Dendreon is committed to supporting men with advanced prostate cancer.

Frequently asked questions about PROVENGE treatment

BACK

When should I consider PROVENGE?

A leading not-for-profit organization NCCN, recommends sipuleucel-T (PROVENGE) as a first-line treatment option in certain men with advanced prostate cancer (mCRPC).

The NCCN recommends sipuleucel-T (PROVENGE) may be used before or after certain other therapies for advanced prostate cancer (mCRPC). Even if you already received treatment for advanced prostate cancer, you may benefit from PROVENGE.

Learn More

PROVENGE & You

Learn more about when and why PROVENGE might be the right treatment for you.

Learn more
PROVENGE & You

The first and only personalized immunotherapy for mCRPC.

Download
Share this page

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed June 21, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Find a doctor and start the PROVENGE conversation

Read and print questions that can help you start the PROVENGE conversation with your doctor.

Talk to your doctor